Status:
COMPLETED
Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Obsessive Compulsive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.
Eligibility Criteria
Inclusion
- Signed informed consent, men and women aged ³18 to £65 years with diagnosis of OCD, at least 12 weeks of treatment with SSRI or clomipramine
Exclusion
- Substance abuse or dependence, female patients who are pregnant, lactating or at risk of pregnancy, known intolerance or lack of response to quetiapine, use of antihypertensive medication with changing doses
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00254735
Start Date
April 1 2002
End Date
March 1 2006
Last Update
December 18 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Freiburg im Breisgau, Germany
2
Research Site
Lübeck, Germany